Fluorouracil

Increased risk of serious, including fatal, adverse reactions in patients with certain homozygous or compound heterozygous DPYD variants: not recommended. Withhold or permanently discontinue if evidence of acute early-onset or unusually severe reactions occur. Consider testing for genetic DYPD variants prior to initiation. Hyperammonemic encephalopathy may occur within 72hrs after initiating therapy; withhold and initiate ammonia-lowering therapy if occurs. Withhold if cardiotoxicity, neurologic toxicity, Grade 3/4 diarrhea, Grade 2/3 palmar-plantar erythrodysesthesia (hand-foot syndrome), Grade 4 myelosuppression, or Grade 3/4 mucositis occurs. Monitor CBCs prior to each treatment cycle, weekly if administered on a weekly or similar schedule, and as needed. Embryo-fetal toxicity. Advise females of reproductive potential and males w. female partners to use effective contraception during and for 3 months after the last dose. Pregnancy (Cat. D): may cause fetal harm. Nursing mothers: not recommended. 

Increased risk of serious, including fatal, adverse reactions in patients with certain homozygous or compound heterozygous DPYD variants: not recommended. Withhold or permanently discontinue if evidence of acute early-onset or unusually severe reactions occur. Consider testing for genetic DYPD variants prior to initiation. Hyperammonemic encephalopathy may occur within 72hrs after initiating therapy; withhold and initiate ammonia-lowering therapy if occurs. Withhold if cardiotoxicity, neurologic toxicity, Grade 3/4 diarrhea, Grade 2/3 palmar-plantar erythrodysesthesia (hand-foot syndrome), Grade 4 myelosuppression, or Grade 3/4 mucositis occurs. Monitor CBCs prior to each treatment cycle, weekly if administered on a weekly or similar schedule, and as needed. Embryo-fetal toxicity. Advise females of reproductive potential and males w. female partners to use effective contraception during and for 3 months after the last dose. Pregnancy (Cat. D): may cause fetal harm. Nursing mothers: not recommended. 

Increased risk of serious, including fatal, adverse reactions in patients with certain homozygous or compound heterozygous DPYD variants: not recommended. Withhold or permanently discontinue if evidence of acute early-onset or unusually severe reactions occur. Consider testing for genetic DYPD variants prior to initiation. Hyperammonemic encephalopathy may occur within 72hrs after initiating therapy; withhold and initiate ammonia-lowering therapy if occurs. Withhold if cardiotoxicity, neurologic toxicity, Grade 3/4 diarrhea, Grade 2/3 palmar-plantar erythrodysesthesia (hand-foot syndrome), Grade 4 myelosuppression, or Grade 3/4 mucositis occurs. Monitor CBCs prior to each treatment cycle, weekly if administered on a weekly or similar schedule, and as needed. Embryo-fetal toxicity. Advise females of reproductive potential and males w. female partners to use effective contraception during and for 3 months after the last dose. Pregnancy (Cat. D): may cause fetal harm. Nursing mothers: not recommended.